Navigation Links
Delcath to Present at the Lazard Healthcare Conference on November 15
Date:11/11/2011

esults to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two system, the timing of our commercial launch in Europe, adoption, use and resulting sales, if any, for  CHEMOSAT in the EEA, our ability to successfully commercialize CHEMOSAT and the potential of the chemosaturation therapy as a treatment for patients with cancers in the liver, acceptability of the clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future Delcath system for chemosaturation in the United States and foreign markets for the same or  other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for CHEMOSAT, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances
'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
2. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
3. FDA Schedules Delcath Pre-New Drug Application Meeting Date
4. Delcath Announces Completion of Regulatory Notification Process in New Zealand
5. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
6. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
7. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
8. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
9. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
10. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
11. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014 Perrigo Company plc, a public limited ... (the " Company "), today announced that it is ... its new 1.30% Senior Notes due 2016 (the " 2016 ... due 2018 (the " 2018 Exchange Notes "), $800,000,000 of ... Exchange Notes ") and $400,00,000 of its new 5.30% Senior ...
(Date:9/2/2014)... 2, 2014  XBiotech announced today interim results ... in the US for its anti-cancer agent Xilonix™. ... therapy, is being evaluated in advanced colorectal cancer ... The primary endpoint of the study is overall ... a control population provided only palliative therapy for ...
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
Breaking Medicine Technology:Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023 and 5.30% Senior Notes Due 2043 4XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... March 7, 2011 Ajinomoto Co., a leader ... safe, effective nutraceutical solutions, has announced that its ... federal trademark registration, (®), on the Principal Register ...  The trademark is the latest milestone for Capsiate ...
... 7, 2011 HGI Global Holdings, Inc., a leading ... today announced the appointment of Michael B. Petras, Jr. ... Mr. Petras, 43, joins HGI from GE Lighting, ... (NYSE: GE ) where he served as ...
Cached Medicine Technology:Ajinomoto Co.'s Capsiate Natura® Reaches New Milestone 2Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader 2Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader 3
(Date:9/2/2014)... September 02, 2014 The Wm. Jennings Bryan ... and public town hall meeting for Veterans and their families ... the outreach fair to provide Veterans with valuable healthcare and ... town hall will provide a forum where we can gather ... , The outreach fair will be held 4:45 p.m. to ...
(Date:9/2/2014)... Essen, Germany, September 2, 2014 In a ... Germany, researchers found that mild cognitive impairment (MCI) ... diabetes mellitus type 2. Interestingly, this strong association ... whereas in older participants (66-80 years) the association ... Journal of Alzheimer,s Disease . , The concept ...
(Date:9/2/2014)... Operators in the Community Services ... annually, arranging care and counsel for those in need. ... expected to derive $39.4 billion in revenue, which includes ... Over the five years through 2014-15, the subdivision is ... including growth of 4.1% in 2014-15. , As the ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... device intended to help with weight loss by blocking a ... expectations in a trial among obese patients. Using electric ... brain and stomach, researchers hoped to suppress feelings of hunger. ... "A device that safely blocks the nerve that connects ...
(Date:9/2/2014)... locations with less intensive (and expensive) practice patterns appear ... spare patients unnecessary and excessive medical care, according to ... , "Growing concern about the costs and harms of ... to avoid the provision of unnecessary care," said lead ... The Dartmouth Institute for Health Policy & Clinical ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2
... within the Academy of Finland,s Research Programme on Substance Use ... aid in smoking reduction therapy. The new drug slows down ... down their smoking. Nicotine is absorbed rapidly through the ... from where it quickly passes through the body and into ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... in a large hospital, more patients died, a new study ... of nursing shortages and cost-cutting, in that the focus should ... the research, appearing in the March 17 issue of the ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... (March 16, 2011) -- On March 28, leading experts ... Congress on Interventional Therapies for Type 2 Diabetes to ... treatment option. The three-day meeting, hosted by NewYork-Presbyterian Hospital/Weill ... together physicians, scientists and policymakers representing 60 countries. The ...
... trial using an all-natural lozenge to treat dry mouth, a ... way at Georgia Health Sciences University College of Dental Medicine. ... closed the faucet, and we want to turn that faucet ... and co-investigator of the study. "The cells and glands that ...
... Young adults are more likely to be heavy drinkers if they ... also had to cope with stressful life events, a new study ... women and 140 men in Germany who were asked about when ... the previous three years, what daily hassles they might have had ...
Cached Medicine News:Health News:New targeted drug helps smokers stub it out 2Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Diabetes Surgery 2nd World Congress 2Health News:Diabetes Surgery 2nd World Congress 3Health News:Diabetes Surgery 2nd World Congress 4Health News:Diabetes Surgery 2nd World Congress 5Health News:Clinical trial for dry mouth funded by international oral care award 2Health News:Drinking Behavior May Be Tied to Early Alcohol Use 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: